Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | SVP, Diagnostics, T-Detect | July 19, 2021 | July 19, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date July 19, 2021 · Filed July 19, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,158 |
Ending reported balance
After 2021-07-19 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-07-19 · Exercise / conversion · Acquired 651 · Balance 9,809 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. Row 2 · 2021-07-19 · Sale · Disposed 651 · Balance 9,158 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.55 · Expires 2030-03-19 | Direct | 104,393 |
Reported balance
After 2021-07-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-07-19 · Exercise / conversion · Disposed 651 · Balance 104,393 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. F2: The options vested with respect to 1/4 of such shares on March 18, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020.
F2: The options vested with respect to 1/4 of such shares on March 18, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 19, 2021 Filed Jul 19, 2021 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 651 | $0.00 Strike: $22.55 | $0.00 |
DisclosureSEC source: 0001209191-21-047304 · doc4.xml · derivative · entry 3 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,393 Underlying: Common Stock · 651 shares Expires 2030-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 18, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| July 19, 2021 Filed Jul 19, 2021 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 651 | $36.12 | $23,514.12 |
DisclosureSEC source: 0001209191-21-047304 · doc4.xml · nonDerivative · entry 2 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,158 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. Read SEC document |
| July 19, 2021 Filed Jul 19, 2021 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 651 | $22.55 | $14,680.05 |
DisclosureSEC source: 0001209191-21-047304 · doc4.xml · nonDerivative · entry 1 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,301 | $0.00 Strike: $22.55 | $0.00 |
DisclosureSEC source: 0001209191-21-042288 · doc4.xml · derivative · entry 6 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,344 Underlying: Common Stock · 1,301 shares Expires 2030-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 18, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,301 | $39.80 | $51,779.80 |
DisclosureSEC source: 0001209191-21-042288 · doc4.xml · nonDerivative · entry 4 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,158 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $39.59 to 40.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 1,301 | $22.55 | $29,337.55 |
DisclosureSEC source: 0001209191-21-042288 · doc4.xml · nonDerivative · entry 3 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 651 | $0.00 Strike: $22.55 | $0.00 |
DisclosureSEC source: 0001209191-21-042288 · doc4.xml · derivative · entry 5 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,345 Underlying: Common Stock · 651 shares Expires 2030-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 18, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 651 | $40.00 | $26,040.00 |
DisclosureSEC source: 0001209191-21-042288 · doc4.xml · nonDerivative · entry 2 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,158 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 651 | $22.55 | $14,680.05 |
DisclosureSEC source: 0001209191-21-042288 · doc4.xml · nonDerivative · entry 1 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. Read SEC document |
| May 18, 2021 Filed May 19, 2021 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 651 | $0.00 Strike: $22.55 | $0.00 |
DisclosureSEC source: 0001209191-21-034234 · doc4.xml · derivative · entry 3 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,996 Underlying: Common Stock · 651 shares Expires 2030-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 18, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| May 18, 2021 Filed May 19, 2021 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 651 | $35.00 | $22,785.00 |
DisclosureSEC source: 0001209191-21-034234 · doc4.xml · nonDerivative · entry 2 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,158 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. Read SEC document |
| May 18, 2021 Filed May 19, 2021 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 651 | $22.55 | $14,680.05 |
DisclosureSEC source: 0001209191-21-034234 · doc4.xml · nonDerivative · entry 1 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 18:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,301 | $0.00 Strike: $22.55 | $0.00 |
DisclosureSEC source: 0001209191-21-027852 · doc4.xml · derivative · entry 3 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,647 Underlying: Common Stock · 1,301 shares Expires 2030-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 18, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 18:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,301 | $41.25 | $53,666.25 |
DisclosureSEC source: 0001209191-21-027852 · doc4.xml · nonDerivative · entry 2 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,158 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 18:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 1,301 | $22.55 | $29,337.55 |
DisclosureSEC source: 0001209191-21-027852 · doc4.xml · nonDerivative · entry 1 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,052 | $0.00 Strike: $22.55 | $0.00 |
DisclosureSEC source: 0001209191-21-022205 · doc4.xml · derivative · entry 5 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, immunoSEQ Dx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,948 Underlying: Common Stock · 16,052 shares Expires 2030-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 18, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,739 | $45.32 | $78,811.48 |
DisclosureSEC source: 0001209191-21-022205 · doc4.xml · nonDerivative · entry 4 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, immunoSEQ Dx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,158 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $44.63 to 45.54, inclusive. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 5,971 | $43.83 | $261,708.93 |
DisclosureSEC source: 0001209191-21-022205 · doc4.xml · nonDerivative · entry 3 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, immunoSEQ Dx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,897 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $43.63 to 44.53, inclusive. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 8,342 | $43.04 | $359,039.68 |
DisclosureSEC source: 0001209191-21-022205 · doc4.xml · nonDerivative · entry 2 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, immunoSEQ Dx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,868 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $42.60 to 43.51, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 16,052 | $22.55 | $361,972.60 |
DisclosureSEC source: 0001209191-21-022205 · doc4.xml · nonDerivative · entry 1 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, immunoSEQ Dx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 19:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 22,894 | $0.00 Strike: $43.68 | $0.00 |
DisclosureSEC source: 0001209191-21-018746 · doc4.xml · derivative · entry 2 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, immunoSEQ Dx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,894 Underlying: Common Stock · 22,894 shares Expires 2021-03-04 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 19:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 9,158 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018746 · doc4.xml · nonDerivative · entry 1 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, immunoSEQ Dx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,158 Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 16:30 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $22.55 | $0.00 |
DisclosureSEC source: 0001209191-20-020640 · doc4.xml · derivative · entry 1 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, immunoSEQ Dx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-03-19 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 18, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.